- NCIt
- C39750
Loading cancer entity…
Loading cancer entity…
Clinical trials
303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (64)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00979862 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00734682 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 34 | University of California, San FranciscoOTHER | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00525525 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma(AVF4120s) | completed | Phase 2 | 74 | University of California, San FranciscoOTHER | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | completed | Phase 1 | 26 | ExelixisINDUSTRY | 1 | Sep 22, 2014 | clinicaltrials |
| NCT01380782 | BIBF 1120 for Recurrent High-Grade Gliomas | completed | Phase 2 | 37 | Patrick Y. Wen, MDOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00609999 | Ph I Dasatinib + Erlotinib in Recurrent MG | completed | Phase 1 | 47 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00612989 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | completed | Phase 1 | 42 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | completed | Phase 2 | 125 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | completed | Phase 2 | 41 | Katy PetersOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00657267 | Dose-Intense Temozolomide in Recurrent Glioblastoma | completed | Phase 2 | 58 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2014 | clinicaltrials |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | completed | Phase 2 | 56 | Duke UniversityOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00612430 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | completed | Phase 2 | 59 | Duke UniversityOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00014170 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00613028 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | completed | Phase 2 | 23 | Duke UniversityOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00612638 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | completed | Phase 1 | 96 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00004262 | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00612339 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00671970 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | completed | Phase 2 | 57 | Duke UniversityOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00316849 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00045565 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00058097 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00615927 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | completed | Phase 2 | 64 | Duke UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00612651 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | completed | Phase 1 | 37 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613132 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | completed | Phase 1 | 78 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | completed | Phase 1 | 49 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00613054 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | completed | Phase 1 | 27 | Annick DesjardinsOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2015source: clinicaltrials